Skip to content

Clinical research on stage differentiation treatment of triple negative breast cancer by integrated traditional and western medicine

Clinical research on stage differentiation treatment of triple negative breast cancer by integrated traditional and western medicine

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-16009517
Enrollment
Unknown
Registered
2016-10-20
Start date
2017-01-31
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

Stage differentiation treatment of integrated traditional and conventional medicine group:Standard conventional medicine treatment plus traditional Chinese medicine
Conventional medicine group:Standard conventional medicine treatment

Sponsors

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Primary breast cancer after surgical treatment, by pathological examination diagnosis for breast malignant epithelial tumors (breast cancer)IHC: ER(-)PR(-), Her-2(-); 2. Patients after surgery; 3. KPS score>=60; 4. Female patients aged 18~75 years; 5. The expeted survival >6 months; 6. No severe organic or functional diseases, drug and food allergies; 7. Willing to accept treatment, observation and the check.

Exclusion criteria

Exclusion criteria: 1. Do not meet the inclusion criteria; 2. Tumor markers continuous elevation or find basin or abdominal cavity viscera have not clear diagnosis of lump, or PET tips with recurrence metastasis; 3. Patients with obstruction can't take Chinese traditional medicine; 4. Pregnant and lactating women; 5. Allergic constitution, and a variety of drug allergy; 6. A serious disease of heart, liver, kidney and hematopoietic system and mental illness patients; 7. Patients were undergoing other drug test.

Design outcomes

Primary

MeasureTime frame
Progression-free survival;1 year survival rate;2 year survival rate;

Secondary

MeasureTime frame
tumor marker;Immunity;quality of life;

Countries

China

Contacts

Public ContactQin Yue Nong

Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine

frank_yching@aliyun.com18917763372

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026